Autoimmune Diseases
Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio
Odyssey Therapeutics; Series D financing; $213 million; autoimmune diseases; clinical pipeline; preclinical programs; precision immunomodulation; RIPK2 inhibitor; PROTAC technology; investors
Vertex forges $2B-plus alliance with Enlaza to create new autoimmune drugs, improve conditioning methods
Vertex Pharmaceuticals; Enlaza Therapeutics; autoimmune diseases; gene therapy; conditioning regimens; War-Lock platform; covalent biologics; drug conjugates; T-cell engagers; biotech alliance
Zenas BioPharma Secures $300M Royalty Deal for Obexelimab FDA Approvals
Zenas BioPharma; Royalty Pharma; Obexelimab; autoimmune diseases; IgG4-Related Disease; Systemic Lupus Erythematosus; FDA approval; royalty agreement; Phase 3 INDIGO trial; funding
J&J Halts Phase 2a Rheumatoid Arthritis Program for Imaavy (Nipocalimab) after Lackluster Results
Johnson & Johnson; Imaavy; nipocalimab; rheumatoid arthritis; Phase 2a trial; DAISY study; clinical trial failure; anti-TNFα therapy; autoimmune diseases
Fosun Licenses Immunology Asset FXS6837 to Sitala in $670M Deal
Fosun Pharma; Sitala; FXS6837; immunology; license agreement; autoimmune diseases; biotech; pharmaceuticals; $670 million
Akeso Scores Two Wins in Phase 3 Trials, Tees Up Regulatory Submissions in China
Akeso; Phase 3 trials; gumokimab; manfidokimab; ankylosing spondylitis; atopic dermatitis; regulatory submission; China; autoimmune diseases; clinical trial results
Bristol Myers Squibb Spins Out Five Immunology Assets into New $300M Biotech with Bain Capital
Bristol Myers Squibb; Bain Capital; immunology; autoimmune disorders; biotech spinout; afimetoran; BMS-986322; clinical development; investment; new company
AstraZeneca’s Self-Administered Myasthenia Gravis Drug Gefurulimab Clears Phase 3 Trial
AstraZeneca; gefurulimab; myasthenia gravis; self-administered drug; Phase 3 trial; PREVAIL trial; C5 inhibitor; autoimmune disease; clinical trial; Alexion acquisition
J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025
Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease
Otsuka Inks $613M Deal for Cantargia’s Autoimmune Antibodies
Otsuka Pharmaceutical; Cantargia; autoimmune diseases; IL1RAP antibodies; CAN10; biotech deal; hidradenitis suppurativa; systemic sclerosis; milestone payments; global commercialization